Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo pill aims to tackle cholesterol in metabolic syndrome patients

NCT ID NCT07523971

Recruiting now Disease control Sponsor: JW Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a fixed-dose combination of two cholesterol-lowering drugs (Pitavastatin and Ezetimibe) in 10,000 adults with high cholesterol and metabolic syndrome. Researchers will track how much LDL ('bad') cholesterol drops after 24 and 48 weeks of treatment in real-world clinics. The goal is to see if this pill works well and is safe for everyday use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pitavastatin/Ezetimibe combination tablet
What this could lead to
If successful, this could confirm that the combination pill effectively lowers cholesterol in real-world patients with metabolic syndrome, supporting its routine use.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. The study is large but early in real-world testing, and individual responses may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome Dyslipidemias hyperlipidemia inherited lipid metabolism disorder metabolic syndrome X

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSLIPIDEMIAS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chungnam National University Hospita

    RECRUITING

    Daejeon, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.